Publications by authors named "A Yemelyanova"
Article Synopsis
- A rare case of endometrial carcinoma with both serous and colorectal carcinoma-like (CRC-like) features is reported, highlighting the complexities of this unusual tumor type.
- The study details the gross, histologic, immunohistochemical, and molecular characteristics of the tumor from diagnosis to surgical resection, supporting its classification as a mixed endometrial carcinoma.
- The rarity of this type of cancer presents significant diagnostic challenges, and the paper reviews existing literature to emphasize the molecular and pathological aspects of similar mixed endometrial carcinomas.
Primary mucinous ovarian carcinoma (MOC) is a rare ovarian epithelial cancer, which is often refractory to chemotherapy. HER2-targeting therapy is being increasingly considered in gynecologic malignancies. Although there have been limited studies examining the HER2 status of such tumors, the criteria for HER2 expression scoring have not been standardized for MOC as it has for other sites.
View Article and Find Full Text PDFMolecular alterations in are well-described as drivers of sporadic gastrointestinal stromal tumors (GISTs) and inflammatory fibroid polyps (IFPs). However, a small number of families with germline mutations in exons 12, 14, and 18 have been reported, forming the basis of an autosomal dominant inherited disorder with incomplete penetrance and variable expressivity, now referred to as -mutant syndrome or GIST-plus syndrome. Phenotypic manifestations of this rare syndrome include multiple gastrointestinal GISTS, IFPs, fibrous tumors, and other variable features.
View Article and Find Full Text PDFArticle Synopsis
- The study examines current practices for assessing HER2 levels in endometrial serous carcinoma (ESC) and colorectal carcinoma (CRC), highlighting that HER2-targeted therapies are increasingly being adopted beyond breast cancer.
- A survey conducted among laboratories showed that a significant portion of them perform in-house HER2 testing, but often rely on guidelines formulated for other types of cancer rather than ESC or CRC-specific standards.
- This inconsistency in HER2 testing practices across laboratories raises concerns about the reliability and applicability of test results, which could impede effective treatment decisions for patients.
Context.—: Neoplastic cellularity assessment has become an essential component of molecular oncology testing; however, there are currently no best practice recommendations or guidelines for this potentially variable step in the testing process.
Objective.